¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report By Technology (MGX, Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic Clinics), By Region, And Segment Forecasts, 2023 - 2030
»óǰÄÚµå
:
1363003
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2023³â 09¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 100 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, Àü ¼¼°è ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 7.6%¸¦ ±â·ÏÇϸç 2030³â¿¡´Â 5¾ï 3,750¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾È±¸°ÇÁ¶Áõ Áõ»ó ¿Ïȸ¦ À§ÇÑ Ç¥ÀûÈµÈ ºñħ½ÀÀû, ºñħ½ÀÀû, ½Å¼ÓÇϰí ȯÀÚ ¼øÀÀÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÄÜÅÃÆ®·»Áî °ú´Ù »ç¿ë, µðÁöÅРȸéÀÇ Àå½Ã°£ ³ëÃâ, ´ç´¢º´, ³ì³»Àå, ¼î±×·» ÁõÈıº µîÀ» À¯¹ßÇÏ´Â À§Çè ¿ä¼ÒÀÇ Àü ¼¼°è ¹ß»ý·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ÀεéÀº ÇÏ·ç Æò±Õ 10½Ã°£ ÀÌ»ó ½Ã°¢Àû µð½ºÇ÷¹ÀÌ ´Ü¸»±â¸¦ »ç¿ëÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
IPL ¹× BBL°ú °°Àº ÷´Ü ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±âÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡Çϱâ À§ÇÑ ÀÓ»ó ¹× ¿¬±¸ Ȱµ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾È°ú ÀÇ·á ºÐ¾ß¿¡¼ ÀÌ·¯ÇÑ Ã·´Ü ±â¼úÀÇ Àû¿ëÀº ¸¹Àº ±¹°¡¿¡¼ Ãʱ⠴ܰ迡 Àֱ⠶§¹®¿¡ ÀÇ·á Á¦°øÀÚÀÇ ½Å·Ú¸¦ ³ôÀ̱â À§Çؼ´Â ÀÓ»óÀû ±Ù°Å°¡ ÇʼöÀûÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ±â¼ú¿¡ ´ëÇÑ ÀÓ»ó ¿¬±¸´Â ¾È±¸°ÇÁ¶Áõ Ä¡·á¿¡¼ ±âÁ¸ Ä¡·á¹ý°ú ºñ±³ÇÏ¿© À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.
´ëü Ä¡·áÀÇ °¡¿ë¼º, IPL/BL Ä¡·áÀÇ ³ôÀº ºñ¿ë, IPL°ú °ü·ÃµÈ ¸¹Àº ±Ý±â »çÇ×, ÀϺΠ±¹°¡ÀÇ È¿À²ÀûÀÎ ÀÇ·á º¸Çè Á¤Ã¥ÀÇ ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, IPLÀ» ÀÌ¿ëÇÑ ¾È±¸°ÇÁ¶Áõ Ä¡·á´Â ¿µ±¹ÀÇ ÁÖ¿ä ÀÇ·á ¼ºñ½º Á¦°øÀÚÀÎ NHS¿¡¼ º¸ÀåÇÏÁö ¾Ê½À´Ï´Ù.
¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- MGX ±â¼úÀº ÀæÀº Á¦Ç° Ãâ½Ã, ºñ¿ë È¿À²¼º, Á¢±Ù¼º Çâ»ó µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À² 41.2%¸¦ Â÷ÁöÇß½À´Ï´Ù.
- IPL ¹× º¹ÇÕ(MGX IPL) ±â¼úÀº °æÁ¦ÀûÀ̰í ÄÄÆÑÆ®ÇÑ Å©±âÀÇ IPL Àåºñ°¡ °³¹ßµÇ°í, ¸ðµç ÇǺλöÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â ´ÙÀç´Ù´ÉÇÔÀ¸·Î ÀÎÇØ Ŭ¸®´Ð ¹× ¾È°ú ¼¾ÅÍÀÇ ¼³Ä¡À²ÀÌ Áõ°¡ÇÏ´Â µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È CAGR 7.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â 2022³â 34.1%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾È±¸°ÇÁ¶Áõ À¯º´·ü Áõ°¡, R&D ºñ¿ë Áõ°¡, ¹Ì±¹°ú ij³ª´Ù¿¡¼ °³ÃֵǴ ´Ù¼öÀÇ ¾È°ú ÇÐȸ ¹× Àü½Ãȸ °³ÃÖ¿¡ ±âÀÎÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®
- ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- BBL
- IPL
- MGX
- º¹ÇÕ(MGX+IPL)
Á¦5Àå ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- º´¿ø
- ¾È°ú Ŭ¸®´Ð
- ±âŸ
Á¦6Àå ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª Àü¸Á
- Áö¿ªº° ¾È±¸°ÇÁ¶Áõ Ä¡·á ±â±â ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ºÏ¹Ì
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- Sight Sciences
- Lumenis
- ESW Vision
- Johnson & Johnson Vision care
- Alcon, Inc.
- MiBo Medical Group
ksm
¿µ¹® ¸ñÂ÷
Dry Eye Treatment Devices Market Growth & Trends:
The global dry eye treatment devices market size is expected to reach USD 537.5 million by 2030, registering a CAGR of 7.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The increasing demand for targeted, non-invasive, faster, and patient-compliant treatment methods to alleviate dry eye symptoms is expected to foster the market growth during the forecast period.
The rising incidence of causative risk factors such as over usage of contact lenses, prolonged exposure to digital screens, diabetes, glaucoma, and Sjogren's syndrome globally is anticipated to propel the growth of the market. For instance, Americans are estimated to spend an average time of more than 10 hours a day at visual display terminals.
The increasing number of clinical and research activities conducted to evaluate the safety and efficacy of advanced dry eye treatment devices such as IPL and BBL will boost the market growth. The application of these advanced technologies in eye care is at a nascent stage in many countries, therefore clinical evidence is essential to increase provider confidence. Besides, clinical studies of these technologies are showing promising results in comparison with conventional treatment methods in dry eye treatment.
The availability of alternative treatment, high cost of IPL/BBL treatment, numerous contraindications associated with IPL, and lack of an efficient health insurance policy in several countries are the factors fueling the growth of the market. For instance, the treatment of dry eye syndrome using intense pulsed light (IPL) is not covered under the NHS, a major provider of healthcare services in the U.K.
Dry Eye Treatment Devices Market Report Highlights:
- The MGX technology held the largest market share 41.2% in 2022 owing to the factors such as frequent product launches, cost-effectiveness, and improving accessibility
- IPL and combination (MGX+IPL) technologies are is anticipated to register a CAGR of 7.6% over the forecast period due to the factors such as the development of economical and compact-sized IPL devices having versatility in treating skin tones of all types, which has boosted its installation rate in clinics and ophthalmic centers
- North America held the largest revenue share of 34.1% in 2022and is anticipated to maintain its dominance over the forecast period. This is attributed to the growing prevalence of dry eye disease, increasing R&D expenditure, and a large number of ophthalmology trade conferences and expos conducted in the U.S. and Canada
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Technology
- 1.1.2. End-use
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. End-use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Dry Eye Treatment Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Dry Eye Treatment Devices Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Dry Eye Treatment Devices: Technology Estimates & Trend Analysis
- 4.1. Dry Eye Treatment Devices Market: Key Takeaways
- 4.2. Dry Eye Treatment Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Broadband Light (BBL)
- 4.3.1. Broadband light (BBL) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Intense Pulsed Light (IPL)
- 4.4.1. Intense pulsed light (IPL) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Meibomian Gland Expression (MGX)
- 4.5.1. Meibomian gland expression (MGX) market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Combination (MGX+IPL)
- 4.6.1. Combination (MGX+IPL) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Dry Eye Treatment Devices: End-use Estimates & Trend Analysis
- 5.1. Dry Eye Treatment Devices Market: Key Takeaways
- 5.2. Dry Eye Treatment Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Hospitals
- 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Ophthalmic Clinics
- 5.4.1. Ophthalmic clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Dry Eye Treatment Devices Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Dry Eye Treatment Devices Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. Saudi Arabia
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. Sight Sciences
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Lumenis
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. ESW Vision
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Johnson & Johnson Vision care
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Alcon, Inc.
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. MiBo Medical Group
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
°ü·ÃÀÚ·á